

Title (en)

BIOLOGICAL COMPOSITIONS, COMPONENTS THEREOF AND USES THEREFOR

Title (de)

BIOLOGISCHE ZUSAMMENSTELLUNGEN, KOMPONENTE DAVON UND ANWENDUNGEN DAFÜR

Title (fr)

COMPOSITIONS BIOLOGIQUES, LEURS CONSTITUANTS ET LEURS APPLICATIONS

Publication

EP 1135476 A4 20060125 (EN)

Application

EP 99957236 A 19991110

Priority

- AU 9900993 W 19991110
- AU PP706098 A 19981111

Abstract (en)

[origin: WO0028009A1] The present invention relates generally to an isolated Hepatitis B virus (HBV) with a surface component exhibiting an altered immunological profile relative to a reference HBV. A reference HBV is considered herein to comprise a composite or consensus nucleotide or amino acid sequence from HBV genotypes A through F. The isolated HBV of the present invention is considered herein to be an HBV variant relative to the reference HBV. The altered immunological profile renders the HBV variants of the present invention less susceptible to vaccines directed to the surface component. The HBV variants of the present invention generally arise from selective pressure following one or both of anti-HBV chemical therapy and in particular chemical therapy aimed at disrupting HBV polymerase activity or function and/or following immune pressure directed to the surface component. Immune pressure may result from natural exposure to HBV or following vaccination with an avirulent or attenuated HBV or with a component of an HBV. The present invention further provides a recombinant polypeptide and derivatives and chemical equivalents thereof corresponding to the surface component of the HBV variants. The HBV variants and recombinant polypeptides and their derivatives and chemical equivalents of the present invention are useful in biological compositions capable of inducing a neutralizing immune response to the HBV variant.

IPC 1-7

C12N 15/00; A61K 39/29; C07K 14/02

IPC 8 full level

C07K 14/02 (2006.01); **C12N 7/04** (2006.01); **A61K 39/00** (2006.01)

CPC (source: EP US)

C07K 14/005 (2013.01 - EP); **C12N 7/00** (2013.01 - EP); **A61K 39/00** (2013.01 - EP US); **C12N 2730/10122** (2013.01 - EP);
C12N 2730/10161 (2013.01 - EP)

Citation (search report)

- [X] WO 9821317 A1 19980522 - WESTERN HEALTH CARE NETWORK [AU], et al
- [X] BARTHOLOMEUSZ A ET AL: "MUTATIONS IN THE HEPATITIS B VIRUS POLYMERASE GENE THAT ARE ASSOCIATED WITH RESISTANCE TO FAMCICLOVIR AND LAMIVUDINE", INTERNATIONAL ANTIVIRAL NEWS, CHURCHILL LIVINGSTONE, EDINBURGH, GB, vol. 5, no. 8, 1997, pages 123 - 124, XP002044248, ISSN: 0965-2310
- [X] AYE THEIN THEIN ET AL: "Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation", JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 26, no. 5, 1997, pages 1148 - 1153, XP002303530, ISSN: 0168-8278
- [X] GHANY M G ET AL: "HEPATITIS B VIRUS S MUTANTS IN LIVER TRANSPLANT RECIPIENTS WHO WERE REINFECTED DESPITE HEPATITIS B IMMUNE GLOBULIN PROPHYLAXIS", HEPATOLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 27, no. 1, January 1998 (1998-01-01), pages 213 - 222, XP009039932, ISSN: 0270-9139
- [XP] BARTHOLOMEUSZ A ET AL: "SIGNIFICANCE OF MUTATIONS IN THE HEPATITIS B VIRUS POLYMERASE SELECTED BY NUCLEOSIDE ANALOGUES AND IMPLICATIONS FOR CONTROLLING CHRONIC DISEASE", VIRAL HEPATITIS REVIEWS, SAUNDERS, PHILADELPHIA, PA, US, vol. 4, no. 3, 1998, pages 167 - 187, XP000863517, ISSN: 1081-7050
- See also references of WO 0028009A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 0028009 A1 20000518; AU PP706098 A0 19981203; CN 1330712 A 20020109; EP 1135476 A1 20010926; EP 1135476 A4 20060125;
HK 1043479 A1 20020913

DOCDB simple family (application)

AU 9900993 W 19991110; AU PP706098 A 19981111; CN 99814393 A 19991110; EP 99957236 A 19991110; HK 02105055 A 20020708